Results 81 to 90 of about 30,272 (291)

Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment

Cells
CAR-T cell therapy is a promising method of cancer treatment, but it has some disadvantages. These disadvantages have led scientists to explore the use of safer CAR-NK cells and new genetic modifications in order to improve the effectiveness of CAR cells.
Tatiana Budagova, Anna Efremova, Margarita Maiak, Dmitry Goldshtein   +3 more
doaj   +1 more source

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies

Frontiers in Immunology, 2022
The great clinical success of chimeric antigen receptor (CAR) T cells has unlocked new levels of immunotherapy for hematological malignancies. Genetically modifying natural killer (NK) cells as alternative CAR immune effector cells is also highly ...
Maren Soldierer, Arthur Bister, Arthur Bister, Corinna Haist, Corinna Haist, Aniththa Thivakaran, Sevgi Can Cengiz, Stephanie Sendker, Nina Bartels, Antonia Thomitzek, Denise Smorra, Maryam Hejazi, Markus Uhrberg, Kathrin Scheckenbach, Cornelia Monzel, Constanze Wiek, Dirk Reinhardt, Naghmeh Niktoreh, Helmut Hanenberg, Helmut Hanenberg   +19 more
doaj   +1 more source

CAR-NK cells for cancer immunotherapy: from bench to bedside

Biomarker Research, 2022
AbstractNatural killer (NK) cells are unique innate immune cells and manifest rapid and potent cytotoxicity for cancer immunotherapy and pathogen removal without the requirement of prior sensitization or recognition of peptide antigens. Distinguish from the T lymphocyte-based cythotherapy with toxic side effects, chimeric antigen receptor-transduced NK
Leisheng Zhang, Yuan Meng, Xiaoming Feng, Zhongchao Han   +3 more
openaire   +3 more sources

Engineered Mesenchymal Stem Cell–NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy

Advanced Science, EarlyView.
IL‐15‐engineered stem cell–NK cell complexes, assembled via bioorthogonal chemistry, enable effective lung cancer immunotherapy. Abstract Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation.
Qian Zhang, Bo Yin, Munaiwaier Sabier, Youlan Yang, Mengling Wu, Zhouping Zhao, Xuanzhi Luo, Yuehong Zhong, Xiuming Zhu, Jie Zhang, Jing Wang, Kai Chen, Fei Ruan, Wei Zhang, Zhimin Lu, Jiong Wang   +15 more
wiley   +1 more source

Loss of Metabolic Fitness Drives Tumor Resistance After CAR-NK Cell Therapy and Can Be Overcome by Cytokine Engineering [PDF]

, 2023
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is promising, with early-phase clinical studies showing encouraging responses.
Acharya, Sunil, Banerjee, Pinaki P, Basar, Rafet, Champlin, Richard E, Chen, Ken, Daher, May, Dou, Jinzhuang, Frede, Julia, Huang, Yuefan, Kaplan, Mecit, Knoechel, Birgit, Laskowski, Tamara J, Li, Li, Li, Ye, Liang, Shaoheng, Lin, Paul, Liu, Enli, Lohr, Jens G, Marin, David, Miao, Qi, Mielke, Stephan, Mohanty, Vakul, Moyes, Judy S, Muniz-Feliciano, Luis, Nandivada, Vandana, Rafei, Hind, Rezvani, Katayoun, Shanley, Mayra, Shpall, Elizabeth J, Vijaykumar, Tushara   +29 more
core   +1 more source

Scalable process development of NK and CAR-NK expansion in a closed bioreactor

Frontiers in Immunology
Production of large amounts of functional NK and CAR-NK cells represents one of the bottlenecks for NK-based immunotherapy. In this study, we developed a large-scale, reliable, and practicable NK and CAR-NK production using G-Rex 100M bioreactors, which ...
Xuening Wang, Maeve Elizabeth Byrne, Chang Liu, Minh Tuyet Ma, Dongfang Liu, Dongfang Liu   +5 more
doaj   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

Process development and scale-up for gene circuit engineered CAR-NK cell manufacturing [PDF]

, 2022
Allogeneic Natural Killer (NK) cell therapy has shown promise in recent years for treating cancer in patients without inducing graft versus host disease and with potential for off-the-shelf administration.
Bakir, Abla, Blanco, Carmina, Gorman, Wesley, Iyer, Dharini, Lakshmireddy, Haritha, Lee, Philip, Nguyen, Denny, Vilchez Juang, Charity, Wood, Travis   +8 more
core   +1 more source

BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer‐Associated Fibroblasts Crosstalk

Advanced Science, EarlyView.
This study reveals that m6A regulators cooperatively upregulate BGN in melanoma, promoting malignancy. Within the tumor microenvironment, CAFs show highest BGN expression. The BGN/MDK axis mediates cancer‐stroma crosstalk, driving normal fibroblast (NF) activation and enhancing the pro‐tumor effect of CAFs, highlighting a promising therapeutic target ...
Hao‐ze Shi, Ming‐yang Wu, Jin‐quan Liu, Cuicui Tian, Li Ma, Xue‐mei Zhou, Ze‐Hao Sun, Zhi‐yong Xu, Run‐dong Zhang, Shan‐yuan Ye, Li‐ming Huang, Yan Wang, Jing‐shu Xiong, Wen‐bo Bu, Xian‐feng Cheng, Jian‐fang Sun, Hao Chen   +16 more
wiley   +1 more source

Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer [PDF]

Colorectal carcinoma (CRC) presents a formidable medical challenge, demanding innovative therapeutic strategies. Chimeric antigen receptor (CAR) natural killer (NK) cell therapy has emerged as a promising alternative to CAR T-cell therapy for cancer.
Boulifa, Abdelhadi, Franzén, Alexander Sebastian, Pecher, Gabriele, Radecke, Clarissa, Raftery, Martin J., Stintzing, Sebastian   +5 more
core   +1 more source